0001209191-23-048179.txt : 20230905 0001209191-23-048179.hdr.sgml : 20230905 20230905164045 ACCESSION NUMBER: 0001209191-23-048179 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230901 FILED AS OF DATE: 20230905 DATE AS OF CHANGE: 20230905 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DeFord John A CENTRAL INDEX KEY: 0001403373 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50744 FILM NUMBER: 231236409 MAIL ADDRESS: STREET 1: C R BARD INC STREET 2: 730 CENTRAL AVENUE CITY: MURRAY HILL STATE: NJ ZIP: 07974 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NUVASIVE INC CENTRAL INDEX KEY: 0001142596 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 330768598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7475 LUSK BLVD CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 909-1800 MAIL ADDRESS: STREET 1: 7475 LUSK BLVD CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-09-01 1 0001142596 NUVASIVE INC NUVA 0001403373 DeFord John A C/O NUVASIVE, INC. 12101 AIRPORT WAY BROOMFIELD CO 80021 1 0 0 0 0 Restricted Stock Unit 2023-09-01 4 D 0 563 0.00 D Common Stock 563 0 D Restricted Stock Unit 2023-09-01 4 D 0 3230 0.00 D Common Stock 3230 0 D Restricted Stock Unit 2023-09-01 4 D 0 2577 0.00 D Common Stock 2577 0 D Restricted Stock Unit 2023-09-01 4 D 0 3095 0.00 D Common Stock 3095 0 D Restricted Stock Unit 2023-09-01 4 D 0 2702 0.00 D Common Stock 2702 0 D Restricted Stock 2023-09-01 4 D 0 3788 0.00 D Common Stock 3788 0 D Restricted Stock Unit 2023-09-01 4 D 0 4816 0.00 D Common Stock 4816 0 D Represented a contingent right to receive one share of the Issuer's common stock upon vesting. Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award. /s/ Nathaniel B. Sisitsky, Attorney-in-Fact for John A. DeFord 2023-09-05